US › Healthcare

Kura Oncology Inc (KURA)

US · Healthcare · Biotechnology

$9.47+3.05%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$18.3M
Revenue YoY
+29.5%
Net profit
$-73.3M
Profit YoY
-27.7%
EPS
$-0.83
EPS estimate
$-0.90
Net margin
-401.5%

EPS came in at -0.83 against a street estimate of -0.90 — a beat of 8.3%.

Key statistics

Market cap
$815.8M
Forward P/E
0.0
P/B
7.42
Book value
$1.22
EPS (TTM)
$-3.35
52-week high
$12.49
52-week low
$5.45
50-day MA
$10.20
200-day MA
$9.64
Beta
0.38

Analyst view

Analysts rate Kura Oncology Inc a strong buy (13 buy, 2 hold, 0 sell out of 15) with an average price target of $31.17.

Shareholding

Insiders
1.43%
Institutions
97.74%

Largest institutional holders

FundStake
BlackRock Inc10.86%
Suvretta Capital Management, LLC9.66%
Bvf Inc9.51%
State Street Corp5.08%
Vanguard Capital Management, LLC4.26%
Armistice Capital, LLC4.21%
Prosight Management, LP3.78%
Deep Track Capital, LP2.98%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kura Oncology Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.